Generic Drug Pathway Curriculum: From ANDA Submission to Global Reliance
Inactive on SAM.gov — responses were due 28 Jul 2026 · No Set aside used · Food and Drug Administration (FDA), HHS · Silver Spring, MD · NAICS 61143 · Solicitation OC-2026-135574
Following NAICS 61143? Get new solicitations in it by email as they post — no account needed.
SAM.gov marked this notice inactive — responses were due 28 July 2026.
No award notice on SAM.gov yet. Not every award is posted there, so this does not mean it went unawarded.
Email me when the award is announced. One email, when SAM.gov posts the award notice. Not every award is posted there; if none appears within six months we'll tell you and stop. No account needed.
This one has closed. We'll email you when new NAICS 61143 solicitations post — the first email lists what is open right now, then at most once a week, only when something new posts. No account needed; unsubscribe in a click.
Description
The U.S. Food and Drug Administration's (FDA), Office of Acquisitions and Grants Services (OAGS), is conducting market research for obtaining Global Abbreviated New Drug Application (ANDA) Training Program services. THIS IS A SOURCES SOUGHT NOTICE (SSN) ONLY. This SSN is being issued in accordance with Federal Acquisition Regulation (FAR) Part 10, Market Research. It is for information, planning, and market research purposes only and is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. The Government reserves the right to contact any of the respondents after the submission deadline if additional information is required. The purpose of this SSN is to identify and gain knowledge of potential business sources and small business sources that are capable of providing the full range of services described in this SSN and the attached Draft Statement of Work (SOW). Responses to this SSN will be utilized for a potential solicitation for an anticipated stand-alone contract for the Global Abbreviated New Drug Application (ANDA) Training Program. The anticipated period of performance for this contract is September 15, 2026 through September 14, 2031 (base year, plus four (4) option years. Requested Information Interested parties are highly encouraged to respond to this SSN by providing the following information in their response: Completed Vendor Feedback Form See attached Vendor Feedback Form If applicable, tracked changes/comments on Draft SOW and Draft Generic Drug Curriculum in MS Word format See attached Draft SOW and attached Draft Global ANDA Training - Generic Drug Curriculum. Capability Statement Responses shall be submitted via email with the subject line "Sources Sought Notice - FDA SSN: OC-2026-135574 to the Contract Specialist, Lawrence Edelmann (lawrence.edelmann@fda.hhs.gov), no later than 12:00pm (Eastern) on July 28, 2026. Attachments Vendor Feedback Form Draft Statement of Work Draft Global ANDA Training - Generic Drug Curriculum
Go deeper on this solicitation
FedSift reads the full solicitation package — every attachment — and pre-extracts the compliance matrix, evaluation factors, key risks, win themes and deal-breakers, each with a verbatim quote and the exact PDF page it came from. It scores the opportunity against your company profile, tells you whether to bid as prime or sub, and ranks teaming partners who could close your gaps.
Source: this notice on SAM.gov. FedSift republishes public federal procurement data and is not affiliated with the U.S. Government. Always confirm dates and requirements against SAM.gov before responding.
